D. M. Hatters, C. A. Peters-libeu, and K. H. Weisgraber, Apolipoprotein E structure: insights into function, Trends Biochem. Sci, vol.31, pp.445-454, 2006.

P. B. Verghese, J. M. Castellano, and D. M. Holtzman, Apolipoprotein E in Alzheimer's disease and other neurological disorders, Lancet Neurol, vol.10, pp.241-252, 2011.

E. H. Corder, A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell et al., Gene dose of apolipoprotein-E type-4 allele and the risk of Alzheimers-disease in late-onset families, Science, vol.261, pp.921-923, 1993.

K. H. Weisgraber and R. W. Mahley, Human apolipoprotein E: The Alzheimer's disease connection, FASEB J, vol.10, pp.1485-1494, 1996.

K. Taddei, R. Clarnette, S. E. Gandy, and R. N. Martins, Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease, Neurosci. Lett, vol.223, pp.29-32, 1997.

V. B. Gupta, S. M. Laws, V. L. Villemagne, D. Ames, A. I. Bush et al., Plasma apolipoprotein E and Alzheimer disease risk The AIBL study of aging, Neurology, vol.76, pp.1091-1098, 2011.

T. Lehtimaki, T. Pirttila, P. D. Mehta, H. M. Wisniewski, H. Frey et al., Apolipoprotein-E (Apoe) polymorphism and its influence on Apoe concentrations in the cerebrospinal-fluid in Finnish patients with Alzheimers-disease, Human Gen, vol.95, pp.39-42, 1995.

R. Scacchi, G. Gambina, M. Ruggeri, M. C. Martini, G. Ferrari et al., Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease, Neurosci. Lett, vol.259, pp.33-36, 1999.

A. J. Slooter, P. De-knijff, A. Hofman, M. Cruts, M. M. Breteler et al., Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study, Neurosci. Lett, vol.248, pp.21-24, 1998.

V. Solfrizzi, F. Panza, A. M. Colacicco, A. D'introno, A. M. Basile et al., Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians, Int. Psychogeriatrics, vol.15, pp.40-41, 2003.

T. A. Addona, X. Shi, H. Keshishian, D. R. Mani, M. Burgess et al., A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease, Nat. Biotechnol, vol.29, pp.635-643, 2011.

L. Anderson and C. L. Hunter, Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins, Mol. Cell. Proteomics, vol.5, pp.573-588, 2006.

B. Domon, A. , and R. , Options and considerations when selecting a quantitative proteomics strategy, Nat. Biotechnol, vol.28, pp.710-721, 2010.

R. Huettenhain, J. Malmstroem, P. Picotti, A. , and R. , Perspectives of targeted mass spectrometry for protein biomarker verification, Curr. Opinion Chem. Biol, vol.13, pp.518-525, 2009.

S. Lin, T. A. Shaler, and C. H. Becker, Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in a single-quadrupole ion trap, Anal. Chem, vol.78, pp.5762-5767, 2006.

R. Schiess, B. Wollscheid, A. , and R. , Targeted proteomic strategy for clinical biomarker discovery, Mol. Oncol, vol.3, pp.33-44, 2009.

S. Surinova, R. Schiess, R. Huettenhain, F. Cerciello, B. Wollscheid et al., On the development of plasma protein biomarkers, J. Proteome Res, vol.10, pp.5-16, 2011.

S. Makawita and E. P. Diamandis, The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification, Clin. Chem, vol.56, pp.212-222, 2010.

N. Rifai, M. A. Gillette, and S. A. Carr, Protein biomarker discovery and validation: the long and uncertain path to clinical utility, Nat. Biotechnol, vol.24, pp.971-983, 2006.

J. R. Whiteaker, C. Lin, J. Kennedy, L. Hou, M. Trute et al., A targeted proteomics-based pipeline for verification of biomarkers in plasma, Nat. Biotechnol, vol.29, pp.625-108, 2011.

S. A. Carr, A. , and L. , Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory?, Clin. Chem, vol.54, pp.1749-1752, 2008.

A. G. Paulovich, J. R. Whiteaker, A. N. Hoofnagle, W. , and P. , The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline, Proteomics Clin. Appl, vol.2, pp.1386-1402, 2008.

A. N. Hoofnagle, J. O. Becker, M. H. Wener, and J. W. Heinecke, Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry, Clin. Chem, vol.54, pp.1796-1804, 2008.

H. Keshishian, T. Addona, M. Burgess, E. Kuhn, and S. A. Carr, Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution, Mol. Cell. Proteomics, vol.6, pp.2212-2229, 2007.

T. Fortin, A. Salvador, J. P. Charrier, C. Lenz, X. Lacoux et al., Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests, Mol. Cell. Proteomics, vol.8, pp.1006-1015, 2009.

Y. Yang, X. Qiang, K. Owsiany, S. Zhang, T. W. Thannhauser et al., Evaluation of different multidimensional LC-MS/MS pipelines for isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic analysis of potato tubers in response to cold storage, J. Proteome Res, vol.10, pp.4647-4660, 2011.

E. Kuhn, T. Addona, H. Keshishian, M. Burgess, D. R. Mani et al., Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry, Clin. Chem, vol.55, pp.1108-1117, 2009.

A. Prakash, T. Rezai, B. Krastins, D. Sarracino, M. Athanas et al., Platform for establishing inter laboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays, J. Proteome Res, vol.9, pp.6678-6688, 2010.

T. A. Addona, S. E. Abbatiello, B. Schilling, S. J. Skates, D. R. Mani et al., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma, Nat. Biotechnol, vol.27, pp.633-85, 2009.

H. Keshishian, T. Addona, M. Burgess, D. R. Mani, X. Shi et al., Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution, Mol. Cell. Proteomics, vol.8, pp.2339-2349, 2009.

E. Kuhn, J. R. Whiteaker, D. R. Mani, A. M. Jackson, L. Zhao et al., Inter-laboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma, Mol. Cell. Proteomics, vol.11, 2012.

A. G. Paulovich, D. Billheimer, A. J. Ham, L. Vega-montoto, P. A. Rudnick et al., Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance, Mol. Cell. Proteomics, vol.9, pp.242-254, 2010.

N. Selevsek, M. Matondo, . Sanchez, M. Carbayo, R. Aebersold et al., Systematic quantification of peptides/proteins in urine using selected reaction monitoring, Proteomics, vol.11, pp.1135-1147, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-02619035

S. Gallien, E. Duriez, and B. Domon, Selected reaction monitoring applied to proteomics, J. Mass Spectrom, vol.46, pp.298-312, 2011.

V. Lange, P. Picotti, B. Domon, A. , and R. , Selected reaction monitoring for quantitative proteomics: a tutorial, Mol. Syst. Biol, vol.4, p.222, 2008.

S. Pan, R. Aebersold, R. Chen, J. Rush, D. R. Goodlett et al., Mass spectrometry based targeted protein quantification: methods and applications, J. Proteome Res, vol.8, pp.787-797, 2009.

E. Shacter, Quantification and significance of protein oxidation in biological samples, Drug Metab. Rev, vol.32, pp.307-326, 2000.

W. Vogt, Oxidation of methionyl residues in proteins -tools, targets, and reversal, Free Radical Biol. Med, vol.18, pp.93-105, 1995.

S. A. Gerber, J. Rush, O. Stemman, M. W. Kirschner, and S. P. Gygi, Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS, Proc. Natl. Acad. Sci. U. S. A, vol.100, pp.6940-6945, 2003.

C. Huillet, A. Adrait, D. Lebert, G. Picard, M. Trauchessec et al., Accurate quantification of cardiovascular biomarkers in serum using Protein Standard Absolute Quantification (PSAQ TM ) and selected reaction monitoring, Mol. Cell. Proteomics, vol.11, 2012.

M. A. Kuzyk, D. Smith, J. Yang, T. J. Cross, A. M. Jackson et al., Multiple reaction monitoringbased, multiplexed, absolute quantitation of 45 proteins in human plasma, Mol. Cell. Proteomics, vol.8, pp.1860-1877, 2009.

J. L. Proc, M. A. Kuzyk, D. B. Hardie, J. Yang, D. S. Smith et al., A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin, J. Proteome Res, vol.9, pp.5422-5437, 2010.

R. Shchepin, M. N. Moeller, H. Y. Kim, D. M. Hatch, S. Bartesaghi et al., Tyrosine-lipid peroxide adducts from radical termination: para coupling and intramolecular diels-alder cyclization, J. Am. Chem. Soc, vol.132, pp.17490-17500, 2010.

H. Fukumoto, M. Ingelsson, N. Garevik, L. O. Wahlund, N. Nukina et al., APOE epsilon 3/epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis, Exp. Neurol, vol.183, pp.249-253, 2003.

K. R. Wildsmith, B. Han, and R. J. Bateman, Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry, Anal. Biochem, vol.395, pp.116-118, 2009.

S. A. Agger, L. C. Marney, and A. N. Hoofnagle, Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquidchromatography-multiple-reaction-monitoring mass spectrometry, Clin. Chem, vol.56, pp.1804-1813, 2010.

B. Ghesquiere, V. Jonckheere, N. Colaert, J. Van-durme, E. Timmerman et al., Redox proteomics of protein-bound methionine oxidation, Mol. Cell. Proteomics, vol.10, 2011.

K. Gevaert, J. Pinxteren, H. Demol, K. Hugelier, A. Staes et al., Four stage liquid chromatographic selection of methionyl peptides for peptide-centric proteome analysis: The proteome of human multipotent adult progenitor cells, J. Proteome Res, vol.5, pp.1415-1428, 2006.

K. Gevaert, J. Van-damme, M. Goethals, G. R. Thomas, B. Hoorelbeke et al., Chromatographic isolation of methionine-containing peptides for gel-free proteome analysis -Identification of more than 800 Escherichia coli proteins, Mol. Cell. Proteomics, vol.1, pp.896-903, 2002.

A. N. Hoofnagle, J. O. Becker, M. N. Oda, G. Cavigiolio, P. Mayer et al., Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures, Clin. Chem, vol.58, pp.777-781, 2012.

M. E. Lassman, T. M. Mclaughlin, E. P. Somers, A. C. Stefanni, Z. Chen et al., A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry, Rapid Commun. Mass Spectrom, vol.26, pp.101-108, 2012.

A. J. Percy, A. G. Chambers, J. Yang, D. Domanski, and C. H. Borchers, Comparison of standard-and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins, Anal. Bioanal. Chem, 2012.

O. Trenchevska, E. Kamcheva, and D. Nedelkov, Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants, Proteomics, vol.11, pp.3633-3641, 2011.

N. L. Anderson, N. G. Anderson, L. R. Haines, D. B. Hardie, R. W. Olafson et al., Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA), J. Proteome Res, vol.3, pp.235-244, 2004.

J. R. Whiteaker, L. Zhao, S. E. Abbatiello, M. Burgess, E. Kuhn et al., Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry, Mol. Cell. Proteomics, vol.10, 2011.

M. Beekman, B. T. Heijmans, N. G. Martin, N. L. Pedersen, J. B. Whitfield et al., Heritabilities of apolipoprotein and lipid levels in three countries, Twin Res, vol.5, pp.87-97, 2002.

D. R. Riddell, H. Zhou, K. Atchison, H. K. Warwick, P. J. Atkinson et al., Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels, J. Neurosci, vol.28, pp.11445-11453, 2008.

M. Beekman, D. Posthuma, B. T. Heijmans, N. Lakenberg, H. E. Suchiman et al., Combined association and linkage analysis applied to the APOE locus, Genetic Epidemiol, vol.26, pp.328-337, 2004.

Y. Uchida, S. Ito, and N. Nukina, Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms, J. Clin. Lab. Anal, vol.14, pp.260-264, 2000.

K. Bohnet, T. Pillot, S. Visvikis, N. Sabolovic, and G. Siest, Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors, J. Lipid Res, vol.37, pp.1316-1324, 1996.

V. Brun, A. Dupuis, A. Adrait, M. Marcellin, D. Thomas et al., Isotope-labeled protein standards, Mol. Cell. Proteomics, vol.6, pp.2139-2149, 2007.

N. Haddy, D. De-bacquer, M. M. Chemaly, M. Maurice, C. Ehnholm et al., The importance of plasma concentration in addition apolipoprotein E to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe, Eur. J. Human Gen, vol.10, pp.841-850, 2002.
URL : https://hal.archives-ouvertes.fr/hal-00176672

F. Schiele, D. De-bacquer, M. Vincent-viry, U. Beisiegel, C. Ehnholm et al., Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project, Atherosclerosis, vol.152, pp.475-488, 2000.

M. J. Artiga, M. J. Bullido, I. Sastre, M. Recuero, M. A. Garcia et al., Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene, Febs Letts, vol.421, pp.105-108, 1998.

L. M. Bekris, S. P. Millard, N. M. Galloway, S. Vuletic, J. J. Albers et al., Ps within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels, J. Alzheimers Dis, vol.13, pp.255-266, 2008.

J. C. Lambert, C. Berr, F. Pasquier, A. Delacourte, B. Frigard et al., Pronounced impact of Th1/E47cs mutation compared with ?491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease, Human Mol. Gen, vol.7, pp.1511-1516, 1998.

J. C. Lambert, T. Brousseau, V. Defosse, A. Evans, D. Arveiler et al., Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations -the ECTIM Study, Human Mol. Gen, vol.9, pp.57-61, 2000.

S. M. Laws, E. Hone, K. Taddei, C. Harper, B. Dean et al., Variation at the APOE-491 promoter locus is associated with altered brain levels of apolipoprotein E, Mol. Psychiatry, vol.7, pp.886-890, 2002.

S. M. Laws, K. Taddei, G. Martins, A. Paton, C. Fisher et al., The ?491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease, Neuroreport, vol.10, pp.879-882, 1999.

M. J. Bullido, M. J. Artiga, M. Recuero, I. Sastre, M. A. Garcia et al., A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia, Nat. Gen, vol.18, pp.69-71, 1998.

G. R. Parker, H. M. Cathcart, R. Huang, I. S. Lanham, E. H. Corder et al., Apolipoprotein gene E4 allele promoter polymorphisms as risk factors for Alzheimer's disease, Psychiatric Gen, vol.15, pp.271-275, 2005.

M. C. Ramos, S. Matias, M. J. Artiga, J. Pozueta, I. Sastre et al., Neuronal specific regulatory elements in apolipoprotein E gene proximal promoter, Neuroreport, vol.16, pp.1027-1030, 2005.

T. Town, D. Paris, D. Fallin, R. Duara, W. Barker et al., The ?491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism, Neurosci. Lett, vol.252, pp.95-98, 1998.

J. C. Wang, J. M. Kwon, P. Shah, J. C. Morris, and A. Goate, Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease, Neurology, vol.55, pp.1644-1649, 2000.

C. E. Yu, H. Seltman, E. R. Peskind, N. Galloway, P. X. Zhou et al., Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: Patterns of linkage disequilibrium and disease/marker association, Genomics, vol.89, pp.655-665, 2007.

J. C. Lambert, A. , and P. , Genetic heterogeneity of Alzheimer's disease: Complexity and advances, Psychoneuroendocrinology, vol.32, pp.62-70, 2007.

J. C. Lambert, A. , and P. , Genetics of Alzheimer's disease: new evidences for an old hypothesis?, Curr. Opinion Gen. Develop, vol.21, pp.295-301, 2011.

K. R. Bales, F. Liu, S. Wu, S. Lin, D. Koger et al., Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice, J. Neurosci, vol.29, pp.6771-6779, 2009.

J. D. Fryer, K. Simmons, M. Parsadanian, K. R. Bales, S. M. Paul et al., Human apolipoprotein E4 alters the amyloid-beta 40 : 42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model, J. Neurosci, vol.25, pp.2803-2810, 2005.

A. M. Fagan, M. Watson, M. Parsadanian, K. R. Bales, S. M. Paul et al., Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease, Neurobiol. Disease, vol.9, pp.305-318, 2002.

D. M. Holtzman, K. R. Bales, T. Tenkova, A. M. Fagan, M. Parsadanian et al., Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A, vol.97, pp.2892-2897, 2000.

.. G. Chiang, P. S. Insel, D. Tosun, N. Schuff, D. Truran-sacrey et al., Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects, vol.75, pp.1976-1981, 2010.

J. C. Morris, C. M. Roe, C. Xiong, A. M. Fagan, A. M. Goate et al., APOE Predicts Amyloid-Beta but Not Tau Alzheimer Pathology in Cognitively Normal Aging, Ann. Neurol, vol.67, pp.122-131, 2010.

E. M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu et al., Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.6820-6825, 2009.

T. Sunderland, N. Mirza, K. T. Putnam, G. Linker, D. Bhupali et al., Cerebrospinal fluid betaamyloid(1-42) and tau in control subjects at risk for Alzheimer's disease: The effect of APOE epsilon 4 allele, Biol. Psychiatry, vol.56, pp.670-676, 2004.

K. Blennow, C. Hesse, and P. Fredman, Cerebrospinal-fluid apolipoprotein-E is reduced in Alzheimers-disease, Neuroreport, vol.5, pp.2534-2536, 1994.

J. Carlsson, V. W. Armstrong, H. Reiber, K. Felgenhauer, and D. Seidel, Clinical Relevance of the Quantification of Apolipoprotein-E in Cerebrospinal-Fluid, Clin. Chim. Acta, vol.196, pp.167-176, 1991.

R. Fukuyama, T. Mizuno, S. Mori, K. Yanagisawa, K. Nakajima et al., Age-dependent decline in the apolipoprotein e level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease, Eur. Neurol, vol.43, pp.161-169, 2000.

C. Hesse, H. Larsson, P. Fredman, L. Minthon, N. Andreason et al., Measurement of apolipoprotein E (apoE) in cerebrospinal fluid, Neurochem. Res, vol.25, pp.511-517, 2000.

S. Kunicki, J. Richardson, P. D. Mehta, K. S. Kim, and E. Zorychta, The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 42, apolipoprotein E and transthyretin in human cerebrospinal fluid, Clin. Biochem, vol.31, pp.409-415, 1998.

M. Landen, C. Hesse, P. Fredman, B. Regland, A. Wallin et al., Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform, Dementia, vol.7, pp.273-278, 1996.

D. Lefranc, P. Vermersch, J. Dallongeville, C. Daemsmonpeurt, H. Petit et al., Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease, Neurosci. Letts, vol.212, pp.91-94, 1996.

N. Rosler, I. Wichart, C. Bancher, and K. A. Jellinger, Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: Impact on non-Alzheimer's dementia?, J. Neural Trans. Supplement, vol.49, pp.259-266, 1996.

I. Skoog, C. Hesser, P. Fredman, L. A. Andreasson, B. Palmertz et al., Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects -Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions, Arch. Neurol, vol.54, pp.267-272, 1997.

H. Song, K. Saito, M. Seishima, A. Noma, K. Urakami et al., Cerebrospinal fluid apo E and apo A-I concentrations in early and late-onset Alzheimer's disease, Neurosci. Letts, vol.231, pp.175-178, 1997.

P. E. Cramer, J. R. Cirrito, D. W. Wesson, C. Y. Lee, J. C. Karlo et al., ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models, Science, vol.335, pp.1503-1506, 2012.